Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 09:30PM GMT
Release Date Price: €13.26 (-7.66%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Good afternoon, and thanks again for joining us for the Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. And our next presenting company is Karyopharm Therapeutics, and it is my pleasure to welcome and introduce CEO, Michael Kauffman, to tell us a little bit about the company.

Before I hand it over to -- hand it over, let me just remind folks that there is a Q&A session after the presentation. Please do feel free to submit a question that I'll ask on your behalf by clicking the ask a question icon. And with that, Michael, take it away.

Michael G. Kauffman
Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director

Thank you very much, Eric. It's great to be here, and thank you all for joining us today to discuss Karyopharm's recent progress in our pursuit of improving the lives of patients with cancer.

Before I begin, let me remind you of the standard remarks I'll make today constitute forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot